Patients with renal impairment (RI) are typically excluded from trials evaluating chimeric antigen receptor (CAR) T cell therapies. We evaluated the outcomes of patients with RI receiving standard of care (SOC) CAR T cell therapy for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this retrospective, single-center cohort study of patients with R/R DLBCL treated with SOC axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) after 2 or more prior lines of therapy, renal and survival outcomes were compared based on RI and fludarabine dose reduction (DR) status. RI was defined by an estimated glomerular filtration rate/min/1.73 m
Wood, A. C., Perez, A. P., Arciola, B., Patel, K., Johnson, G., DiMaggio, E., Bachmeier, C. A., Reid, K., Carallo, S., Vargas, M. H., Faramand, R., Chavez, J. C., Shah, B., Gaballa, S., Khimani, F., Elmariah, H., Nishihori, T., Lazaryan, A., Freeman, C., Davila, M. L., … Jain, M. D. (2022). Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplantation and cellular therapy, 28(12), 829.e1–829.e8. https://doi.org/10.1016/j.jtct.2022.09.009